🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccine recommendations, a particular individual has emerged somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning Covid shots in the global health crisis and has zeroed in on possible deaths following Covid immunization in her brief position at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Program

Agency leaders had intended to announce radical revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the global community with little proof for improved outcomes. The announcement has been pushed back until the next year.

In place of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric immunization guidelines in the US so as to align more similar to Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – usually the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Background

Høeg has little discernible background in drug development, regulation or administrative roles, which has been customary for previous directors of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous directors of the center would “grasp legal statutes and the science of medication creation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran CBER have had.”

This division has an vast portfolio at the FDA, the former commissioner emphasized.

“Many people just pays attention on the innovative therapies, but the generic program authorizes thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant management aspect to the job, which manages in excess of 5,000 staff members. “It is a enormous administrative position, if you execute it properly,” the former official concluded.

Agency Reaction and Controversial Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among agency officials on vaccines, a representative said that the “concerns are based on inaccurate assumptions”.

“This background is consistent with the responsibilities of her position,” the spokesperson said, citing the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a contentious expedited drug-approval program that apparently concerned her preceding directors. “How are these medications being selected for this fast-track system? Who is making the decisions?” Dr. Howard said. “There is a lot of confidentiality happening at the agency right now.”

In general, he stated, “the FDA looks to be trending towards less stringent rules of all drugs, with the exception of immunizations.”

Documented History on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, past, Howard said. She authored a analysis using unverified crowd-sourced reports to estimate the incidence of myocarditis following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new administration featured revising regulations for new vaccines and discontinuing “unnecessary” vaccines, she remarked post-election on a online show. At the FDA, Høeg has reportedly suggested preventing young men from obtaining Covid vaccinations.

“She’s an thorough dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the science in a very misleading, untruthful way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|